Global Therapeutic Plasma Exchange Market – Snapshot

Plasma exchange is a procedure that separates and removes plasma from the blood in order to eliminate a disease substance circulating in the plasma. The red blood cells, white blood cells, and platelets are returned to the patient, along with a prescribed replacement fluid. Plasma exchange is widely performed in the treatment of various chronic diseases as first line or as second line of therapy or as a supportive treatment. Plasmapheresis is a procedure that filters the blood and removes harmful antibodies. Plasmapheresis can be conducted in two forms: plasma exchange and plasma perfusion. In plasma exchange, a large portion of plasma containing toxins and other abnormal matter is removed from the other components of blood and replaced with replacement fluid, either fresh frozen plasma (FFP) i.e., donor plasma or albumin. In plasma perfusion, the separated plasma is treated by second membrane filtration or an adsorptive column for the removal of abnormal components. Treated plasma is then returned to the patient, thereby eliminating the requirement of replacement fluids.

therapeutic plasma exchange market.

The global therapeutic plasma exchange (TPE) market was valued at US$ 1,063.38 Mn in 2017 and is anticipated to expand at a CAGR of 7.5% from 2018 to 2026 to reach US$ 2,015.93 Mn by 2026. Rise in prevalence of chronic diseases, increase in applications of therapeutic plasma exchange, and intensive research and clinical trials being performed to determine the efficacy of plasma exchange over other treatments are the factors expected to fuel the growth of the market during the forecast period.

Therapeutic plasma exchange (TPE) has wide applications in the treatment of neurological, renal, hematological, and metabolic disorders. The indications for using therapeutic plasma exchange procedures as a line of treatment are regulated through guidelines provided by the American Society for Apheresis (ASFA). It categorizes the indications in four parts: category I to IV. Category I and II depict TPE as first or second line of treatment for many neurological, renal, and hematological disorders such as chronic inflammatory demyelinating polyneuropathy (CIDP), myasthenia gravis, Guillain-Barre syndrome, and thrombotic thrombocytopenic purpura (TTP).

The global therapeutic plasma exchange (TPE) market has been segmented based on disease indication, end-user, and region. In terms of disease indication, the neurological disorders segment is estimated to account for a major share of the market. Therapeutic plasma exchange is effective in treating certain neurological conditions and also recommended as first line of treatment in these indications. For instance, long term use of plasma exchange has been proved to be effective in managing the sudden and severe attack in multiple sclerosis. Moreover, increase in incidence of chronic disorders has pushed researchers to develop new and alternative therapies. For instance, Guillain-Barre syndrome (GBS) patients when treated with plasma exchange showed a significant improvement compared to patients with supportive care alone. Evidence-based usage of plasmapheresis in neurology and increase in application areas are likely to drive the segment.

Based on end-user, the hospitals segment constituted a major share of the market in 2017. The segment is likely to expand at the highest growth rate during the forecast period. Dominance of the hospitals segment is attributed to rise in the number of patients with autoimmune diseases and increased number of patients coming in through reimbursement programs such as Medicare. Additionally, increase in consolidation in health care facilities and rise in the number of physicians shifting from private clinics to large scale hospitals propel the hospitals segment.

In terms of region, the global therapeutic plasma exchange (TPE) market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. Developed regions such as North America and Europe accounted for leading shares of the global market in 2017. The large base of biopharmaceutical companies and research and academic institutes in these regions have contributed to the leading share of these regions. Moreover, rapid expansion and increase in number of research and academic institutes in these regions are expected to propel demand for therapeutic plasma exchange procedures during the forecast period. The market in Asia Pacific is projected to expand at an exponential growth rate, owing to rapidly improving health care facilities in countries such as India, China, South Korea, and Malaysia. China dominated the therapeutic plasma exchange market in Asia Pacific, whereas the market in India is anticipated to record significant growth during the forecast period. Moreover, increase in investments by leading market players  is expected to augment the market in the region. These factors are likely to drive demand for therapeutic plasma exchange in the near future. The market in Latin America and Middle East & Africa is projected to witness steady growth during the forecast period.

Prominent players in the global therapeutic plasma exchange market include Asahi Kasei Corporation , Baxter International, Inc., Terumo Corporation , B. Braun Melsungen AG , Fresenius Kabi AG, Kawasumi Laboratories, Inc., Haemonetics Corporation, Cerus Corporation, Hemacare Corporation, and Medica S.p.A.

Global Therapeutic Plasma Exchange Market: Scope and Methodology

This report analyzes the current and future prospects of the global therapeutic plasma exchange market. The report comprises a comprehensive executive summary, including a market snapshot that provides overall information of various segments. The report is a combination of primary and secondary research. Primary research formed the bulk of the research efforts along with information collected from telephonic interviews and interactions via e-mails. Secondary research involved study of company websites, annual reports, press releases, stock analysis presentations, and various international and national databases. The report provides market size in terms of US$ Mn for each segment for the period from 2016 to 2026, considering the macro and micro environmental factors. Growth rates for each segment within the global therapeutic plasma exchange market have been determined after a thorough analysis of past trends, demographics, future trends, technological developments, and regulatory requirements.

A detailed qualitative analysis of factors responsible for driving and restraining market growth and future opportunities has been provided in the overview section. The report also provides insights into the key trends of the therapeutic plasma exchange market such as rise in prevalence of autoimmune diseases, cost advantage over IVIG treatment, and improvement in health care infrastructure in emerging economies. Key market indicators influencing the global therapeutic plasma exchange market, including cost constraints and regulatory landscape, have been taken into consideration. The report also includes market attractiveness analysis of the major segments that provides a thorough analysis of the overall competitive scenario in the global therapeutic plasma exchange market.

Market revenue in terms of US$ Mn for the period between 2016 and 2026 along with the compound annual growth rate (CAGR %) from 2018 to 2026 are provided for all the segments, considering 2017 as the base year. The year-on-year growth of the global therapeutic plasma exchange market for each segment is also provided. Additionally, market-related factors such as favorable reimbursement scenario, expanding applications in chronic diseases, side effects associated with plasmapheresis and historical year-on-year growth have been taken into consideration while estimating the market size.

Global Therapeutic Plasma Exchange Market: Segmentation

Based on disease indication, the global therapeutic plasma exchange market has been segmented into neurological disorders, renal disorders, hematology disorders, metabolic disorders, and others. The neurological disorders segment has been classified into chronic inflammatory demyelinating polyneuropathy, myasthenia gravis, multiple sclerosis, neuromyelitis optica, and Guillain-Barré syndrome. The renal disorders segment has been categorized into post-renal transplant rejection, anti-glomerular basement membrane (anti-GMB) disease, and Wegener’s granulomatosis. The hematology disorders segment has been divided into thrombotic thrombocytopenic purpura, hemolytic uremic syndrome, cryoglobulinemia, multiple myeloma, metabolic disorders, familial hypercholesterolaemia (homozygous), and fulminant Wilson disease. In terms of end-user, the market has been classified into hospitals, specialty clinics, and ambulatory surgical centers. The hospitals segment is expected to dominate the market during the forecast period.

In terms of region, the global therapeutic plasma exchange market has been segment into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. Additionally, the regions have been divided into major countries/sub-regions in each of the regions. These include the U.S., Canada, the U.K., Germany, Russia, France, Italy, Spain, China, Australia, Japan, India, Brazil, GCC Countries, South Africa, and Mexico.

Global Therapeutic Plasma Exchange Market: Competitive Landscape

The report also profiles major players in the global therapeutic plasma exchange market based on various attributes such as company overview, financial overview, SWOT analysis, key business strategies, product portfolio, and recent developments. Key companies profiled in the report include Asahi Kasei Corporation, Baxter International, Inc., Terumo Corporation, B. Braun Melsungen AG, Fresenius Kabi AG, Kawasumi Laboratories, Inc., Haemonetics Corporation, Cerus Corporation, Hemacare Corporation, and Medica S.p.A. 

The global therapeutic plasma exchange market has been segmented as follows:

Global Therapeutic Plasma Exchange Market, by Disease Indication

  • Neurological Disorders
    • Chronic Inflammatory Demyelinating Polyneuropathy
    • Myasthenia Gravis
    • Multiple Sclerosis
    • Neuromyelitis Optica
    • Guillain-Barré Syndrome
  • Renal Disorders
    • Post-renal Transplant Rejection
    • Anti-GBM (Glomerular Basement Membrane) Disease
    • Wegener’s Granulomatosis
  • Hematology Disorders
    • Thrombotic Thrombocytopenic Purpura
    • Hemolytic Uremic Syndrome
    • Cryoglobulinemia
    • Multiple Myeloma
  • Metabolic Disorders
    • Familial Hypercholesterolaemia (homozygous)
    • Fulminant Wilson Disease
  • Others

Global Therapeutic Plasma Exchange Market, by End-user

  • Hospitals
  • Specialty Clinics
  • Ambulatory Surgical Centers

 Global Therapeutic Plasma Exchange Market, by Region

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • U.K.
    • France
    • Spain
    • Italy
    • Russia
    • Rest of Europe
  • Asia Pacific
    • Australia & New Zealand
    • Japan
    • China
    • India
    • Rest of Asia pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa
    • GCC Countries
    • South Africa
    • Israel
    • Rest of Middle East & Africa
.